Cargando…

An Open Access Database of Licensed Cancer Drugs

A global, comprehensive and open access listing of approved anticancer drugs does not currently exist. Partial information is available from multiple sources, including regulatory authorities, national formularies and scientific agencies. Many such data sources include drugs used in oncology for sup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pantziarka, Pan, Capistrano I, Rica, De Potter, Arno, Vandeborne, Liese, Bouche, Gauthier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991999/ https://www.ncbi.nlm.nih.gov/pubmed/33776770 http://dx.doi.org/10.3389/fphar.2021.627574

Ejemplares similares

A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021)

Repurposing Infectious Diseases Vaccines Against Cancer
por: Vandeborne, Liese, et al.
Publicado: (2021)

Drug repurposing as a potential source of innovative therapies in cervical cancer
por: Capistrano I., Rica, et al.
Publicado: (2022)

“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
por: Pantziarka, Pan, et al.
Publicado: (2018)

ReDO_DB: the repurposing drugs in oncology database
por: Pantziarka, Pan, et al.
Publicado: (2018)

Does the oncology community have a rejection bias when it comes to repurposed drugs?
por: Gyawali, Bishal, et al.
Publicado: (2018)

Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2015)

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent
por: Sukhatme, Vidula, et al.
Publicado: (2015)

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
por: Pantziarka, Pan, et al.
Publicado: (2016)

Open access, copyright and licensing: basics for open access publishers
por: Morrison, Heather, et al.
Publicado: (2016)

Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents
por: Pantziarka, Pan, et al.
Publicado: (2018)

Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
por: Van Nuffel, An MT, et al.
Publicado: (2015)

The Repurposing Drugs in Oncology (ReDO) Project
por: Pantziarka, Pan, et al.
Publicado: (2014)

Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
por: Verbaanderd, Ciska, et al.
Publicado: (2017)

A Computational Model of Tumor Growth and Anakoinosis
por: Pantziarka, Pan, et al.
Publicado: (2019)

Closing the access gap for health innovations: an open licensing proposal for universities
por: Chaifetz, Samantha, et al.
Publicado: (2007)

Product Licenses Database Application
por: Tonkovikj, Petar
Publicado: (2016)

Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?
por: Bognar, Cinthia Leite Frizzera Borges, et al.
Publicado: (2016)

Ontology-Based Meta-Analysis of Animal and Human Adverse Events Associated With Licensed Brucellosis Vaccines
por: Xie, Jiangan, et al.
Publicado: (2018)

Interstate Reciprocity in Licensing
por: Potter, William Warren
Publicado: (1906)

Recycling existing drugs for cancer therapy: delivering low cost cancer care
por: Pantziarka, Pan, et al.
Publicado: (2014)

Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium
por: Vandeborne, Liese, et al.
Publicado: (2019)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016)

Open by default: a proposed copyright license and waiver agreement for open access research and data in peer-reviewed journals
por: Hrynaszkiewicz, Iain, et al.
Publicado: (2012)

Drug-Repositioning Approaches Based on Medical and Life Science Databases
por: Zamami, Yoshito, et al.
Publicado: (2021)

Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database
por: Magro, Lara, et al.
Publicado: (2021)

Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases
por: Hecker, Michael, et al.
Publicado: (2022)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Serious Adverse Drug Reactions and Safety Signals in Children: A Nationwide Database Study
por: Vieira, Jean Mendes de Lucena, et al.
Publicado: (2020)

Editorial: Drug Repurposing
por: Pantziarka, Pan, et al.
Publicado: (2019)

Sales trends of psychotropic drugs in the COVID-19 pandemic: A national database study in Brazil
por: Del Fiol, Fernando de Sá, et al.
Publicado: (2023)

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
por: Satake, Riko, et al.
Publicado: (2021)

Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
por: Soe, Kay Khine, et al.
Publicado: (2023)

Medical Education and State Examinations for License
por: Potter, William Warren
Publicado: (1898)

Medical Education and State Examinations for License
por: Potter, William Warren
Publicado: (1898)

Medical Education and State License Examinations
por: Potter, William Warren
Publicado: (1897)

Cannot write session to /tmp/vufind_sessions/sess_k40kspujho4lal8bb5g99snl2b